EMBC vs NVO
EMBC: A global leader in diabetes injection devices now expanding into broad-based medical supplies and drug delivery platforms through strategic acquisitions. NVO: A global leader in the development of pharmaceutical treatments for diabetes, obesity, and rare chronic diseases, anchored by its prominent GLP-1 therapy portfolio.
Side-by-side fundamentals
| Metric | EMBC | NVO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $5.75 | $38.18 | |
| Market cap | $326M | $206.0B | |
| P/E | 3.03 | 11.40 | EMBC lower |
| Net margin FY2025, SEC XBRL | +8.8% | +33.1% | NVO higher |
| Gross margin FY2025, SEC XBRL | +62.6% | +81.0% | NVO higher |
| Operating margin FY2025, SEC XBRL | +22.4% | +41.3% | NVO higher |
| ROE FY2025, SEC XBRL | n/a | +52.8% | |
| ROA FY2025, SEC XBRL | +8.7% | +18.9% | NVO higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.63 | EMBC lower |
| Revenue growth (YoY) as of 2026-09-03 | -3.4% | +5.6% | NVO higher |
| Revenue CAGR (3y) SEC XBRL | -1.5% | +20.4% | NVO higher |
| Dividend yield as of 2026-09-03 | +0.8% | +2.7% | NVO higher |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-09-03 | 0.95 | 0.81 | |
| 1-year return as of 2026-10-08 close | -58.4% | -36.0% | NVO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.